1. Risk of depression, suicide and psychosis with hydroxychloroquine treatment for rheumatoid arthritis: A multinational network cohort study
- Author
-
Edward Burn, Anthony G. Sena, David Vizcaya, Marcel de Wilde, Peter R. Rijnbeek, Benjamin Skov Kaas-Hansen, Albert Prats-Uribe, Haini Wen, Osaid Alser, Laura Hester, Jill Hardin, Mees Mosseveld, Carlos Areia, H Morgan-Stewart, Gowtham A. Rao, Patrick B. Ryan, Thamir M. Alshammari, Jennifer C E Lane, Kristin Kostka, Juan M. Banda, George Hripcsak, Kristine E. Lynch, Christian G. Reich, James Weaver, Paula Casajust, Sajan Khosla, Kristina Fišter, Danielle Newby, Rae Woong Park, Fredrik Nyberg, Simon Lovestone, Maria Tereza Fernandes Abrahão, Seng Chan You, Patricia Biedermann, Matthew E. Spotnitz, Spyros Kolovos, Daniel Prieto-Alhambra, Daniel R. Morales, Marc A. Suchard, Vignesh Subbian, Paras P. Mehta, Anna Ostropolets, Heba Alghoul, Junqing Xie, Azza Shoaibi, Talita Duarte-Salles, Rupa Makadia, Lin Zhang, Medical Informatics, and consortium, OHDSI-COVID-19
- Subjects
Male ,0301 basic medicine ,Poison control ,Suicide prevention ,Arthritis, Rheumatoid ,Cohort Studies ,0302 clinical medicine ,Germany ,Epidemiology ,Medicine ,Pharmacology (medical) ,psychosis ,030212 general & internal medicine ,Suicidal ideation ,AcademicSubjects/MED00360 ,Depression (differential diagnoses) ,Depression ,Hazard ratio ,HCQ ,Middle Aged ,3. Good health ,Suicide ,Antirheumatic Agents ,Original Article ,Female ,medicine.symptom ,Hydroxychloroquine ,Cohort study ,safety ,Adult ,medicine.medical_specialty ,Adolescent ,depression ,epidemiology, RA ,Risk Assessment ,Psychoses, Substance-Induced ,Suicidal Ideation ,Young Adult ,03 medical and health sciences ,Rheumatology ,SDG 3 - Good Health and Well-being ,Humans ,Psychiatry ,Aged ,business.industry ,Proportional hazards model ,United Kingdom ,United States ,COVID-19 Drug Treatment ,030104 developmental biology ,business - Abstract
Author(s): Lane, Jennifer CE; Weaver, James; Kostka, Kristin; Duarte-Salles, Talita; Abrahao, Maria Tereza F; Alghoul, Heba; Alser, Osaid; Alshammari, Thamir M; Areia, Carlos; Biedermann, Patricia; Banda, Juan M; Burn, Edward; Casajust, Paula; Fister, Kristina; Hardin, Jill; Hester, Laura; Hripcsak, George; Kaas-Hansen, Benjamin Skov; Khosla, Sajan; Kolovos, Spyros; Lynch, Kristine E; Makadia, Rupa; Mehta, Paras P; Morales, Daniel R; Morgan-Stewart, Henry; Mosseveld, Mees; Newby, Danielle; Nyberg, Fredrik; Ostropolets, Anna; Woong Park, Rae; Prats-Uribe, Albert; Rao, Gowtham A; Reich, Christian; Rijnbeek, Peter; Sena, Anthony G; Shoaibi, Azza; Spotnitz, Matthew; Subbian, Vignesh; Suchard, Marc A; Vizcaya, David; Wen, Haini; Wilde, Marcel de; Xie, Junqing; You, Seng Chan; Zhang, Lin; Lovestone, Simon; Ryan, Patrick; Prieto-Alhambra, Daniel; OHDSI-COVID-19 consortium | Abstract: ObjectivesConcern has been raised in the rheumatology community regarding recent regulatory warnings that HCQ used in the coronavirus disease 2019 pandemic could cause acute psychiatric events. We aimed to study whether there is risk of incident depression, suicidal ideation or psychosis associated with HCQ as used for RA.MethodsWe performed a new-user cohort study using claims and electronic medical records from 10 sources and 3 countries (Germany, UK and USA). RA patients ≥18 years of age and initiating HCQ were compared with those initiating SSZ (active comparator) and followed up in the short (30 days) and long term (on treatment). Study outcomes included depression, suicide/suicidal ideation and hospitalization for psychosis. Propensity score stratification and calibration using negative control outcomes were used to address confounding. Cox models were fitted to estimate database-specific calibrated hazard ratios (HRs), with estimates pooled where I2 l40%.ResultsA total of 918 144 and 290 383 users of HCQ and SSZ, respectively, were included. No consistent risk of psychiatric events was observed with short-term HCQ (compared with SSZ) use, with meta-analytic HRs of 0.96 (95% CI 0.79, 1.16) for depression, 0.94 (95% CI 0.49, 1.77) for suicide/suicidal ideation and 1.03 (95% CI 0.66, 1.60) for psychosis. No consistent long-term risk was seen, with meta-analytic HRs of 0.94 (95% CI 0.71, 1.26) for depression, 0.77 (95% CI 0.56, 1.07) for suicide/suicidal ideation and 0.99 (95% CI 0.72, 1.35) for psychosis.ConclusionHCQ as used to treat RA does not appear to increase the risk of depression, suicide/suicidal ideation or psychosis compared with SSZ. No effects were seen in the short or long term. Use at a higher dose or for different indications needs further investigation.Trial registrationRegistered with EU PAS (reference no. EUPAS34497; http://www.encepp.eu/encepp/viewResource.htm? id=34498). The full study protocol and analysis source code can be found at https://github.com/ohdsi-studies/Covid19EstimationHydroxychloroquine2.
- Published
- 2020
- Full Text
- View/download PDF